Sarcoidosis, vasculitis, and diffuse lung diseases : official journal of WASOG最新文献

{"title":"Comparison of the 2022 ACR/EULAR classification criteria with the 1990 ACR classification criteria for Takayasu arteritis.","authors":"Duygu Tecer, Mehmet Nur Kaya, Özlem Kılıç, Sedat Yılmaz","doi":"10.36141/svdld.v42i3.17094","DOIUrl":"10.36141/svdld.v42i3.17094","url":null,"abstract":"<p><strong>Background and aim: </strong>Takayasu arteritis (TAK) mostly affects the aorta and its major branches and has an unclear origin. This study aimed to compare the 1990 American College of Rheumatology (ACR) classification criteria with the 2022 ACR/European League Against Rheumatism (EULAR) classification criteria for TAK on the basis of clinical data analysis of patients with TAK and other major vascular diseases.</p><p><strong>Methods: </strong>This retrospective study was conducted in a single-center. The results included 34 TAK patients routinely followed at a tertiary rheumatology center from October 2017 to February 2024. The accuracy, sensitivity, specificity, positive predictive values (PPV), negative predictive values (NPV), and area under the receiver operating characteristic (ROC) curve (AUC) of the classification criteria were compared.</p><p><strong>Results: </strong>The sensitivity (91.2%), specificity (90.9%), PPV (93.9%), NPV (86.9%), accuracy (94.4%) and AUC (0.983 (0.957-0.998)) of the 2022 ACR/EULAR classification criteria for TAK were higher than those of the 1990 ACR classification criteria for TAK (76.4%, 86.3%, 88.9%, 64.2% and 0.75, respectively), and the difference in AUC was statistically significant (0.860 (0.757-0.963), p < 0.001).</p><p><strong>Conclusions: </strong>This study found that the 2022 ACR/EULAR classification criteria were more suitable for our patient population and had better classification performance than those in 1990, which can be supported in clinical practice. Our study needs to be supported by future multicenter prospective studies with larger patient numbers.</p>","PeriodicalId":502142,"journal":{"name":"Sarcoidosis, vasculitis, and diffuse lung diseases : official journal of WASOG","volume":"42 3","pages":"17094"},"PeriodicalIF":0.0,"publicationDate":"2025-09-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12536845/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145202682","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Use of 18F-FDG PET in assessing response to treatment in adults with pulmonary sarcoidosis: A systematic literature review.","authors":"Oliver Vij, Mathangi Krishnakumar, Helen Elwell, Mrinalini Dey, Koushan Kouranloo","doi":"10.36141/svdld.v42i3.16631","DOIUrl":"10.36141/svdld.v42i3.16631","url":null,"abstract":"<p><strong>Background and aim: </strong> Symptoms, severity and response to treatment of sarcoidosis can follow a heterogenous pattern, presenting a clinical challenge. Use of Fludeoxyglucose F18 Positron Emission Tomography (18F-FDG PET) in disease monitoring remains uncertain. We undertook a systematic literature review on the use of 18F-FDG PET in assessing response to treatment in adults with pulmonary sarcoidosis.</p><p><strong>Methods: </strong> Articles discussing 18F-FDG PET use in response to treatment in pulmonary sarcoidosis published until January 2024 were included. All article types were eligible except opinion pieces, case reports, case series of ≤10 patients and reviews.</p><p><strong>Results: </strong> Time between baseline 18F-FDG PET and follow-up scan ranged from 2 to 6 months. Compared to clinical response, sensitivity of 18F-FDG PET in determining response to treatment ranged from 56% to 100%, with mean sensitivity of 75.3% (SD 16.0).</p><p><strong>Conclusions: </strong>18F-FDG PET could be considered in monitoring response to immunosuppression in patients with pulmonary sarcoidosis.</p>","PeriodicalId":502142,"journal":{"name":"Sarcoidosis, vasculitis, and diffuse lung diseases : official journal of WASOG","volume":"42 3","pages":"16631"},"PeriodicalIF":0.0,"publicationDate":"2025-09-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12536847/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145202692","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Residential fungal β-(1,3)-D-glucan exposure is associated with decreased pulmonary function in fibrotic pulmonary sarcoidosis.","authors":"Emma M Stapleton, Nervana Metwali, Michael Shlossman, Linder Wendt, Alejandro A Pezzulo, Nabeel Y Hamzeh, Alejandro P Comellas, Peter S Thorne, Alicia K Gerke","doi":"10.36141/svdld.v42i3.16831","DOIUrl":"10.36141/svdld.v42i3.16831","url":null,"abstract":"<p><strong>Background and aim: </strong>Sarcoidosis is a multi-system disease frequently affecting the lungs. It is thought to be mediated by gene-environment interaction; for example, epidemiological data show organic aerosol exposure increases risk of pulmonary sarcoidosis. The aim of this study was to assess whether exposure to bioaerosol associates with worse lung disease in patients with pulmonary sarcoidosis.</p><p><strong>Methods: </strong>Using an observational, cohort study design, we measured residential exposure to fungal and bacterial cell wall material, β-(1,3)-D-glucan (BDG) and endotoxin, respectively, in healthy control subjects and those with pulmonary sarcoidosis. In the case cohort, we compared bioaerosol concentrations to pulmonary disease severity, assessed by pulmonary function testing, qualitative chest computed tomography (CT), and serum biomarkers. Log-transformed bioaerosol concentrations were compared to lung function and significance and correlation determined by Pearson correlation.</p><p><strong>Results: </strong>Homes of subjects with sarcoidosis had higher BDG and endotoxin concentrations than control subjects. Patients with significant pulmonary fibrosis had greater disease severity (Wasfi severity score, visual analogue scale) and reduced pulmonary function compared to those without fibrosis (all P<0.01). Residential fungal BDG correlated with declining FVC, only in patients with fibrosis on CT imaging (P=0.02). Survey data revealed higher BDG concentrations were found in homes of cat-owners, and the number of houseplants owned correlated with declines in FVC and FEV1 (P=0.05 and 0.02, respectively). In patients without fibrosis, eight inflammatory markers correlated with BDG (6CKine/CCL21, IL-9, IL-17F, IL-21, IL-28A, I-309, MIP-1β, TARC), while in those with pulmonary fibrosis, BDG correlated with two inflammatory markers (Eotaxin-3, M-CSF), suggesting immune anergy to inhaled antigens in patients with fibrosis.</p><p><strong>Conclusions: </strong>In patients with pulmonary fibrosis, disease severity was correlated with residential exposure to fungal cell wall material, but not gram-negative bacterial cell wall material. These patients may experience immune anergy to inhaled antigens.</p>","PeriodicalId":502142,"journal":{"name":"Sarcoidosis, vasculitis, and diffuse lung diseases : official journal of WASOG","volume":"42 3","pages":"16831"},"PeriodicalIF":0.0,"publicationDate":"2025-09-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12536839/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145202697","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Use of fatigue assessment scale and small fiber neuropathy screening list in Japanese patients with sarcoidosis.","authors":"Hiromi Tomioka, Yu Kobayashi, Masaaki Iwabayashi, Masamichi Lee, Tasuku Matsuoka, Makoto Yokota, Hisanori Amimoto, Junji Takiguchi, Masahiro Kaneko, Hiroshi Fujii","doi":"10.36141/svdld.v42i3.16824","DOIUrl":"10.36141/svdld.v42i3.16824","url":null,"abstract":"<p><strong>Background: </strong>The Fatigue Assessment Scale (FAS) and Small Fiber Neuropathy Screening List (SFNSL) are widely used in Western countries to investigate symptoms associated with fatigue and small fiber neuropathy (SFN). However, few studies have used these patient-reported outcome measures (PROMs) in Japan.</p><p><strong>Methods: </strong>This was a cross-sectional and longitudinal study at an outpatient clinic in a community teaching hospital in Japan. Participants completed the FAS, SFNSL, and Short Form-36. Clinical parameters, including angiotensin-converting enzyme (ACE) and soluble interleukin-2 receptor (sIL2R), were derived from the medical records of the patients.</p><p><strong>Results: </strong>The study population included 55 patients (29 males; 26 females; mean age: 59±15 years; median disease duration: 5.0 years). Eleven patients received a systemic corticosteroid. The mean FAS score was 22.7±8.2; 27 patients (49.1%) and five patients (9.1%) indicated fatigue (score: ≥22) and extreme fatigue (score: ≥35), respectively. The mean SFNSL score was 13.8±14.3; 23 patients (41.8%) and two patients (3.6%) indicated probable/highly probable SFN (score: 11-48) and SFN (score: ≥49), respectively. The FAS score exhibited strong correlations with physical function, vitality, and mental health of Short Form-36. The SFNSL score exhibited strong correlations with bodily pain and vitality. Of the 55 patients, 45 completed the 1-year follow-up. There were no significant changes noted in the FAS score (mean: 0.04, 95% confidence interval: -1.29-1.38) and SFNSL score (mean: 0.31, 95% confidence interval: -2.12-2.74) during the follow-up. Within-subject changes in FAS and SFNSL scores showed moderate correlations with those of physical function and general health, respectively. There was no significant relationship between FAS or SFNSL score and ACE or sIL2R values at baseline and within-subject changes in these parameters during the follow-up.</p><p><strong>Conclusions: </strong>Approximately half of the patients suffered from fatigue or SFN. These nonspecific symptoms have a great effect on quality of life.</p>","PeriodicalId":502142,"journal":{"name":"Sarcoidosis, vasculitis, and diffuse lung diseases : official journal of WASOG","volume":"42 3","pages":"16824"},"PeriodicalIF":0.0,"publicationDate":"2025-09-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12536842/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145202731","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Diagnostic potential of serum ACE and CBC inflammatory markers in silicosis in the ceramic workers.","authors":"Bilge Akgündüz","doi":"10.36141/svdld.v42i3.16985","DOIUrl":"10.36141/svdld.v42i3.16985","url":null,"abstract":"<p><p>This study aims to determine whether serum sACE and CBC inflammatory markers can be used to diagnose silicosis and assess its severity. 231 subjects referred to Eskişehir City Hospital Occupational Diseases Polyclinic between January 2021 and January 2024 were examined. Groups classified into silicosis (n:131), non-silicosis (n:40), and control groups (n:40). sACE and CBC inflammatory markers were analyzed. ROC curve assessed. sACE levels were markedly elevated (85.19±36.06 U/L) in cases with higher profusion scores and disease categories compared to control and non-silicosis groups. sACE has a high diagnostic value for silicosis detection and severity assessment (AUC:0.810,p=0.001). Platelet/Lymphocyte Ratio (PLR) and Monocyte/Lymphocyte Ratio (MLR) were significant predictors of advanced silicosis with large opacities (AUC for PLR: 0.796, p=0.001; AUC for MLR: 0.726, p=0.004). Serum ACE and CBC inflammatory indices serve as valuable biomarkers for diagnosing silicosis and determining disease severity.</p>","PeriodicalId":502142,"journal":{"name":"Sarcoidosis, vasculitis, and diffuse lung diseases : official journal of WASOG","volume":"42 3","pages":"16985"},"PeriodicalIF":0.0,"publicationDate":"2025-09-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12536841/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145202670","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"IL17 in Sarcoidosis - A level playing field?","authors":"Deepak Nagra, Hassan Choudry, Joy Odia, Akshay Balaji, Katie Bechman, Mark Russell, Maryam Adas, Zijing Yang, Chamith Rosa, Siwalik Banerjee, Tim Blake, Nicola Gullick, James Galloway","doi":"10.36141/svdld.v42i2.16288","DOIUrl":"10.36141/svdld.v42i2.16288","url":null,"abstract":"<p><p></p>","PeriodicalId":502142,"journal":{"name":"Sarcoidosis, vasculitis, and diffuse lung diseases : official journal of WASOG","volume":"42 2","pages":"16288"},"PeriodicalIF":0.0,"publicationDate":"2025-06-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12242868/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144693020","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"EBUS/EUS-guided lymph nodal gadolinium injection and MRI of the chest in diagnosis of abnormal lymphatic drainage. A case series.","authors":"Venerino Poletti, Simone Petrarulo, Emanuela Giampalma, Claudia Ravaglia, Sara Piciucchi","doi":"10.36141/svdld.v42i2.16539","DOIUrl":"10.36141/svdld.v42i2.16539","url":null,"abstract":"<p><p>Impaired lymphatic circulation in the mediastinum may result from congenital disorders, leakage secondary to trauma, or infiltration by neoplasia. It manifests as chylothorax, plastic bronchitis, and/or alveolar fatty pneumonitis. Lymphography, involving the injection of contrast medium into peripheral lymph nodes, was previously utilised but posed challenges in execution and image interpretation. We describe two patients admitted to our department with relapsing chylothorax and respiratory failure associated with \"fatty\" pneumonitis and plastic bronchitis. The final diagnosis was confirmed by injecting 2 mL of gadolinium into the mediastinal lymph nodes under endoscopic ultrasonography guidance (EBUS), and magnetic resonance imaging (MRI) visualised its distribution.</p>","PeriodicalId":502142,"journal":{"name":"Sarcoidosis, vasculitis, and diffuse lung diseases : official journal of WASOG","volume":"42 2","pages":"16539"},"PeriodicalIF":0.0,"publicationDate":"2025-06-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12242876/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144693017","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Mental health burden in progressive pulmonary fibrosis and idiopathic pulmonary fibrosis: Depression and anxiety.","authors":"Jovan Javorac, Dejan Živanović, Miljana Miladinović, Andrijana Mikić, Vesna Dukanac, Miroslav Ilić, Ana Milenković, Sonja Peričević Medić, Tamara Popović, Svetlana Kašiković Lečić","doi":"10.36141/svdld.v42i2.16342","DOIUrl":"10.36141/svdld.v42i2.16342","url":null,"abstract":"<p><strong>Background and aim: </strong>Progressive pulmonary fibrosis (PPF) is an umbrella term for several interstitial lung diseases characterized by the progressive proliferation of fibrous tissue within the lung interstitium. This study aimed to assess the prevalence of depressive and anxiety symptoms among PPF patients and their repercussions on quality of life.</p><p><strong>Methods: </strong>Thirty-seven PPF patients undergoing treatment at the Institute for Pulmonary Diseases of Vojvodina, Serbia were enrolled. The SGRQ questionnaire assessed quality of life, while the DASS-21 questionnaire evaluated anxiety and depression symptoms. Sociodemographic and clinical factors were correlated with questionnaires outcomes, and the influence of anxiety and depression symptoms on quality of life was examined.</p><p><strong>Results: </strong>Anxiety symptoms were detected in 56.75% of PPF patients and were more prevalent in patients previously diagnosed with depression and/or anxiety. Depression symptoms were detected in 45.95% of PPF patients and were more pronounced in the patients with longer duration of PPF, and positive history of malignancies. Stress symptoms were linked to lower PaO2 values and were detected in 37.84% of participants. HRQL was moderately to severely decreased and was lower in patients who, in addition to PPF, also suffered from other respiratory diseases, and was statistically significantly associated with lower DLCO values. A statistically significant correlation has been proven between the presence of anxiety, depression, and stress symptoms and HRQL, as measured through the \"Symptoms\" and \"Impact\" subscales of the SGRQ questionnaire.</p><p><strong>Conclusions: </strong>Anxiety and depression symptoms are highly prevalent among PPF patients, exerting substantial impacts on their quality of life.</p>","PeriodicalId":502142,"journal":{"name":"Sarcoidosis, vasculitis, and diffuse lung diseases : official journal of WASOG","volume":"42 2","pages":"16342"},"PeriodicalIF":0.0,"publicationDate":"2025-06-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12242862/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144693022","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Advanced interstitial lung disease: Evidence-based management and clinical approach.","authors":"Zein Kattih, Zachary Greenstein, Priyanka Makkar, Rohit Gupta","doi":"10.36141/svdld.v42i2.16206","DOIUrl":"10.36141/svdld.v42i2.16206","url":null,"abstract":"<p><strong>Background: </strong>Interstitial lung disease (ILD) is a heterogeneous group of diseases characterized by clinical, physiologic, and radiologic abnormalities. Advanced ILD (sometimes referred to as end-stage interstitial lung disease) is characterized by either gradual or rapid progressive decline of pre-existing or newly diagnosed ILD with worsening of symptoms, pulmonary function tests, six-minute walk test (6MWT) distance, and/or imaging findings, specifically high-resolution computed tomography (HRCT) imaging of the chest affecting patient's quality of life. Special considerations are required for the management of patients with these advanced ILDs, particularly those who will ultimately require lung transplantation. Though several society and expert panels provide guidance on ILD management, there are none focused specifically on the approach to patients with advanced ILD.</p><p><strong>Objectives: </strong>In this review, we attempt to define advanced ILD and identify the clinical considerations required for diagnosis and management of patients with advanced ILD.</p><p><strong>Discussion: </strong>Pathophysiologic mechanisms of ILD and complications are not completely understood but include inflammation, fibrosis, pulmonary hypertension, venous thromboembolism, recurrent infections, and aspiration. Management of these patients includes consideration of anti-fibrotic medications, anti-inflammatory/immunosuppressive medications and treatment of concurrent pulmonary hypertension as indicated on a case-by-case basis. Non-pharmacologic management with supplemental oxygen, pulmonary rehabilitation, and palliative care are tailored to each patient's clinical status. Finally, early referral to lung transplantation is critical, as advanced ILD can be fatal, and sometimes rapidly so.</p><p><strong>Conclusion: </strong>Advanced ILD is an oftentimes fatal group of heterogeneous diseases that have varying managements depending on underlying subtype. Identification of progressive disease and complications are the first steps to management of these patients to optimize lung function and quality of life and improve outcomes before lung transplantation.</p>","PeriodicalId":502142,"journal":{"name":"Sarcoidosis, vasculitis, and diffuse lung diseases : official journal of WASOG","volume":"42 2","pages":"16206"},"PeriodicalIF":0.0,"publicationDate":"2025-06-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12242865/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144693014","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Chest radiography in interstitial lung disease: Accuracy and radiological features from a systematic review and meta-analysis.","authors":"Ruaa Mustafa Qafesha, Mahmoud Diaa Hindawi, Menna Elbadry, Israa Sharabati, Doaa Mashaly, Muhiddin Dervis, Qasi Najah, Muataz Kashbour","doi":"10.36141/svdld.v42i2.16108","DOIUrl":"10.36141/svdld.v42i2.16108","url":null,"abstract":"<p><strong>Background: </strong>This systematic review aims to summarize and evaluate the diagnostic performance of chest X-ray (CXR) compared with high-resolution computed tomography (HRCT) for detecting interstitial lung disease (ILD).</p><p><strong>Research question: </strong>what is the diagnostic accuracy and radiological finding of CXR in ILD, using HRCT as a gold standard.</p><p><strong>Study design and method: </strong>We systematically searched electronic databases to find studies evaluating the diagnostic accuracy of CXR and HRCT for detecting ILD. We used StataMP/17 and R statistical software for the quantitative analysis. Values like pooled sensitivity, specificity, positive likelihood ratio, negative likelihood ratio, diagnostic odds ratio with their 95% confidence interval, and the SROC curve was performed.</p><p><strong>Results: </strong>We included a total of 18 studies involving 1917 patients. Compared to HRCT, CXR had sensitivity of 0.62 (95% CI: 0.47-0.74), specificity of 0.90 (95% CI: 0.85 - 0.93), positive likelihood ratio of 5.9 (95% CI 4.5-7.7), negative likelihood ratio of 0.43 (95% CI 0.31, 0.59), diagnostic odds ratio of 14 (95% CI 9 - 21), and area under the ROC curve of 0.88 (95% CI 0.85-0.91). Deek's plot showed no publication bias (p= 0.44). CXR had lower sensitivity compared with HRCT in detecting specific radiologic findings. Subgroup analysis revealed that a patient sample surpassing 100 indicated significantly higher specificity.</p><p><strong>Conclusion: </strong>Chest radiography exhibits moderate sensitivity and high specificity for detecting ILD when HRCT is regarded as the gold standard test. Although CXR is recommended as an initial diagnostic tool, it should not be solely relied upon for a definitive diagnosis, as it might miss some cases.</p>","PeriodicalId":502142,"journal":{"name":"Sarcoidosis, vasculitis, and diffuse lung diseases : official journal of WASOG","volume":"42 2","pages":"16108"},"PeriodicalIF":0.0,"publicationDate":"2025-06-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12242875/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144693016","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}